GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
Exact Sciences
Who owns Exact Sciences?
Exact Sciences shifted to GAAP profitability after launching Cologuard Plus in early 2025, moving from growth-driven capital burn to institutional consolidation. Founded in 1995, it grew from molecular colorectal diagnostics to a diversified cancer‑screening leader headquartered in Madison, Wisconsin.
Ownership is now concentrated among large institutional investors and mutual funds, with founders’ stakes diluted over time and executive leadership guiding strategic direction; see Exact Sciences Porter's Five Forces Analysis for competitive context.
Who Founded Exact Sciences?
Exact Sciences was co-founded in 1995 by Stanley Lapidus and Anthony Shuber; early ownership concentrated with the founders and venture backers as the company developed DNA-based stool testing.
Founders' Roles
Stanley Lapidus provided strategic vision; Anthony Shuber led scientific development and assay design.
Early Investors
Venture capital firms, notably Mayfield Fund, led seed and early rounds to fund clinical validation.
Equity Allocation
Founders and early employees held significant minority stakes with typical four-year vesting schedules.
IPO and Dilution
Exact Sciences went public on Nasdaq in January 2001, raising approximately $54,000,000, triggering founder dilution as institutional capital entered.
Governance Provisions
Initial agreements included standard buy-sell clauses and lock-up periods typical for early-stage IPOs.
Transition of Control
Over the following decade founding stakes were largely recycled via secondary offerings and option pools, shifting control to professional management by 2009.
Early ownership history influences current Exact Sciences ownership structure and shareholder composition; see further context in Marketing Strategy of Exact Sciences.
Key facts and implications
Founders-to-investors transition shaped governance, dilution, and later institutional ownership patterns.
- Founders: Stanley Lapidus (visionary) and Anthony Shuber (lead scientist).
- Lead early investor: Mayfield Fund provided foundational capital.
- IPO: January 2001, raised approximately $54,000,000, increasing institutional shareholders.
- By 2009, founding equity largely recycled; professional management assumed stewardship.
Complete Exact Sciences Strategy Bundle
- 6 Full Frameworks, 1 Company – All Pre-Researched
- Each Framework Fully Sourced with Real Company Data
- Built for Strategy Courses, Case Studies & MBA Programs
- Adapt to Your Assignment – No Starting from Scratch
- 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's
How Has Exact Sciences’s Ownership Changed Over Time?
Key events reshaping Exact Sciences ownership include Kevin Conroy’s 2009 CEO appointment and fundraising through secondary offerings and convertible debt, the pivotal $2.8 billion Genomic Health acquisition in 2019, and institutional consolidation through 2025 as the stock became a core healthcare index holding.
| Event | Year / Amount | Impact on Ownership |
|---|---|---|
| Kevin Conroy appointed CEO; funding clinical trials | 2009; multiple secondary offerings & convertible debt | Shift from early private holders to broader institutional base |
| Acquisition of Genomic Health | $2.8 billion (2019) | Integrated precision oncology investors; expanded institutional shareholder mix |
| Institutional ownership concentration | Early 2025; ~97.5% institutional ownership | Majority of shares held by global asset managers; reduced insider percentage |
As of early 2025, Exact Sciences ownership is overwhelmingly institutional, with key shareholders exerting outsized governance influence despite insiders holding under 2% of outstanding equity.
Major stakeholders and ownership facts
Institutional giants dominate the shareholder registry, with a small but strategic insider stake linked to executive RSUs and performance awards.
- Vanguard Group — approximately 11.8% of outstanding shares
- BlackRock — approximately 9.4%
- State Street Corporation — approximately 5.2%
- ARK Investment Management — roughly 3.6% per latest 13F filings
Insider ownership, including CEO Kevin Conroy and other executives, remains below 2%, maintained largely through restricted stock units and performance-based awards that align management with institutional investors and long-term shareholder value; see more in this analysis of the company’s strategic moves in Growth Strategy of Exact Sciences.
From PESTLE Factors to Full Strategy Bundle
- PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
- Every Strategic Angle Covered – Nothing Left to Research
- Pre-filled with Company-Specific Research
- No Missing Sections for Your Case Study
- One Download Covers Your Entire Company Analysis
Who Sits on Exact Sciences’s Board?
Exact Sciences' board of directors comprises 11 members and is chaired by Kevin Conroy, who serves as both Chairman and Chief Executive Officer; the board blends independent directors and industry executives, including former Genzyme CFO Michael Wyzga and BVI Medical CEO Shervin Korangy, with no single controlling investor represented.
| Director | Role / Background | Independence |
|---|---|---|
| Kevin Conroy | Chairman & Chief Executive Officer; leads company strategy | Not independent |
| Michael Wyzga | Former CFO, Genzyme; finance and M&A expertise | Independent |
| Shervin Korangy | President & CEO, BVI Medical; medical device and commercial experience | Independent |
| Other directors (8) | Mix of biotech, diagnostics, finance, and commercial leaders | Majority independent |
The board's composition supports governance for a publicly traded company focused on revenue growth and MCED pipeline expansion, with 2025 estimated revenue of $3.1 billion cited as a key rationale for institutional support despite CEO duality.
Board control and voting dynamics
The company uses a one-share-one-vote structure, and top institutional holders drive most proxy outcomes.
- Major institutional investors: Vanguard, BlackRock, State Street collectively hold the largest passive stakes
- No dual-class shares or super-voting stock; voting rights align with share ownership
- Board has avoided high-profile proxy fights by addressing profitability and MCED development
- Insiders hold a minority of total voting power; no single individual controls the company
For historical context on Exact Sciences ownership and corporate evolution, see Brief History of Exact Sciences.
Exact Sciences Business Model + Strategy Bundle
- Ideal for Essays, Case Studies & Slides
- Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
- Company-Specific Content Already Organized
- One Bundle Replaces Days of Independent Research
- Buy the Bundle Once. Use Across All Your Assignments
What Recent Changes Have Shaped Exact Sciences’s Ownership Landscape?
Over the past three years Exact Sciences ownership has shifted from dispersed growth-era holders to more concentrated positions held by value-oriented institutional funds and passive vehicles, driven by improved free cash flow in late 2024 and strategic capital returns in 2024–2025.
| Metric | Recent Value | Implication |
|---|---|---|
| Share repurchase | $500,000,000 completed in 2024 | Increased share concentration; reduced public float |
| Institutional holders | Over 900 distinct entities as of 2025 | Influx of healthcare-focused mutual funds after Cologuard Plus launch |
| Free cash flow | Positive beginning late 2024 | Shift from high-burn growth to cash-generative model |
Ownership trends show rising allocations from passive index funds and large-cap growth investors prioritizing margin expansion and commercialization of next-gen blood-based screening tests; founder dilution is complete and leadership succession is a noted analyst focus while management reiterates an independent, platform-based strategy.
Share Repurchase Impact
The $500 million 2024 buyback reduced float and modestly increased remaining holders' percentage stakes, favoring long-term institutional owners and passive funds.
Cologuard Plus Launch
The 2025 rollout attracted new healthcare mutual funds and pushed institutional holders beyond 900, altering the mix of Exact Sciences investors.
Acquisition Rumors
Consolidation in diagnostics has generated persistent speculation about potential acquirers, though management affirms continued independence and platform growth.
Governance & Succession
Founder ownership is zero in filings and Kevin Conroy's >15-year tenure raises succession planning as a material ownership-governance consideration for shareholders.
For related operational and revenue details see Revenue Streams & Business Model of Exact Sciences
From Five Forces to Full Company Analysis
- Includes SWOT, PESTLE, BMC, BCG and 4P's
- Pre-Researched with Company-Specific Data
- Best Value for a Complete Analysis
- Ready to Adapt for Your Case Study
- Ready for Essays and Slidesd
- What is Brief History of Exact Sciences Company?
- What is Competitive Landscape of Exact Sciences Company?
- What is Growth Strategy and Future Prospects of Exact Sciences Company?
- How Does Exact Sciences Company Work?
- What is Sales and Marketing Strategy of Exact Sciences Company?
- What are Mission Vision & Core Values of Exact Sciences Company?
- What is Customer Demographics and Target Market of Exact Sciences Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.